Stockscreener 앱 받기
39.18
4.56%
-1.87
전일 마감가:
$41.05
열려 있는:
$41.74
하루 거래량:
846.22K
Relative Volume:
1.16
시가총액:
$3.29B
수익:
$399.58M
순이익/손실:
$-54.04M
주가수익비율:
-52.24
EPS:
-0.75
순현금흐름:
$40.13M
1주 성능:
-4.69%
1개월 성능:
-10.14%
6개월 성능:
+23.87%
1년 성능:
+59.66%
1일 변동 폭
$38.44
$41.81
1주일 범위
$38.44
$42.34
52주 변동 폭
$18.61
$47.32
Veracyte Inc Stock (VCYT) Company Profile
명칭
Veracyte Inc
전화
(650) 243-6300
주소
6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA
VCYT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VCYT
Veracyte Inc
|
39.18 | 3.29B | 399.58M | -54.04M | 40.13M | -0.75 |
|
TMO
Thermo Fisher Scientific Inc
|
532.55 | 203.70B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
210.23 | 151.18B | 23.88B | 3.90B | 5.30B | 5.28 |
|
A
Agilent Technologies Inc
|
135.37 | 38.62B | 6.51B | 1.29B | 1.37B | 4.42 |
|
IDXX
Idexx Laboratories Inc
|
452.77 | 37.07B | 3.90B | 887.87M | 808.08M | 10.67 |
|
IQV
Iqvia Holdings Inc
|
191.04 | 33.64B | 15.41B | 1.37B | 2.11B | 7.50 |
Veracyte Inc Stock (VCYT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-05 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-10-16 | 개시 | UBS | Buy |
| 2024-10-10 | 개시 | Guggenheim | Buy |
| 2024-02-23 | 재확인 | Needham | Buy |
| 2023-01-18 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2023-01-05 | 개시 | Scotiabank | Sector Outperform |
| 2022-01-07 | 개시 | Stephens | Overweight |
| 2021-11-18 | 재개 | Goldman | Buy |
| 2021-06-15 | 개시 | Raymond James | Outperform |
| 2021-02-18 | 재개 | Needham | Buy |
| 2021-01-28 | 개시 | Truist | Buy |
| 2020-11-10 | 개시 | KeyBanc Capital Markets | Sector Weight |
| 2020-09-09 | 개시 | Morgan Stanley | Underweight |
| 2019-07-31 | 개시 | Lake Street | Buy |
| 2019-07-02 | 개시 | Needham | Buy |
| 2018-11-29 | 다운그레이드 | Janney | Buy → Neutral |
| 2018-10-31 | 업그레이드 | Janney | Neutral → Buy |
| 2017-11-07 | 다운그레이드 | Janney | Buy → Neutral |
| 2017-11-07 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2017-08-31 | 재개 | BTIG Research | Buy |
| 2016-11-14 | 재개 | Leerink Partners | Outperform |
| 2015-12-18 | 개시 | Cantor Fitzgerald | Buy |
| 2015-06-11 | 재확인 | Leerink Partners | Outperform |
| 2013-11-26 | 개시 | William Blair | Outperform |
모두보기
Veracyte Inc 주식(VCYT)의 최신 뉴스
Is Veracyte Stock a Good Addition to Your Portfolio Right Now? - Nasdaq
Veracyte (VCYT) Expected to Announce Quarterly Earnings on Monday - MarketBeat
8,074 Shares in Veracyte, Inc. (NASDAQ:VCYT) Acquired by Convergence Investment Partners LLC - MarketBeat
Veracyte to Participate in Upcoming Investor Conferences - WICZ
Can Veracyte's March Conference Circuit Signal Major Strategic Updates? - StockTitan
Rice Hall James & Associates LLC Decreases Holdings in Veracyte, Inc. (NASDAQ:VCYT) - MarketBeat
The Latest Breaking News from VCYT - Inkl
VCYT: 3 Emerging Biotech Firms Pioneering Next-Gen Therapies - StockNews.com
Veracyte, Inc. (NASDAQ:VCYT) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World
Veracyte (NASDAQ:VCYT) Cut to “Hold” at StockNews.com - Defense World
Veracyte Stock Soars to 52-Week High, Reaching $46.12 - MSN
Veracyte (NASDAQ:VCYT) Upgraded by StockNews.com to Buy Rating - MarketBeat
New Data at ASCO GU Show Power of Veracyte’s Decipher Tests to Improve Patient Care and Its GRID Tool to Advance Prostate and Bladder Cancer Research - 01Net
Veracyte (NASDAQ:VCYT) Trading Down 7.1%What's Next? - MarketBeat
Sumitomo Mitsui Trust Group Inc. Sells 259,006 Shares of Veracyte, Inc. (NASDAQ:VCYT) - MarketBeat
Veracyte Announces 17 Abstracts Demonstrating Its Decipher Tests’ Leadership in Urologic Cancers to Be Presented at the 2025 ASCO GU Symposium - BioSpace
Veracyte, Inc. (NASDAQ:VCYT) CFO Rebecca Chambers Sells 527 Shares - MarketBeat
Jennison Associates LLC Raises Stock Position in Veracyte, Inc. (NASDAQ:VCYT) - MarketBeat
Blue Trust Inc. Cuts Position in Veracyte, Inc. (NASDAQ:VCYT) - Defense World
Veracyte CFO Rebecca Chambers sells $23,108 in stock - MSN
KBC Group NV Boosts Stock Position in Veracyte, Inc. (NASDAQ:VCYT) - Defense World
Caprock Group LLC Sells 555 Shares of Veracyte, Inc. (NASDAQ:VCYT) - Defense World
Veracyte CFO Rebecca Chambers sells $23,108 in stock By Investing.com - Investing.com Australia
Insider Sell: Rebecca Chambers Sells Shares of Veracyte Inc (VCY - GuruFocus.com
Veracyte CFO Sells Shares Under Pre-arranged Trading Plan - TradingView
New Study Shows Veracyte’s Decipher Bladder Test Predicts Disease Upstaging in Patients with Bladder Cancer - BioSpace
Veracyte to Release Fourth Quarter and Full-Year 2024 Financial Results on February 24, 2025 - Business Wire
Veracyte (NASDAQ:VCYT) Sets New 52-Week High After Analyst Upgrade - MarketBeat
6,621 Shares in Veracyte, Inc. (NASDAQ:VCYT) Purchased by Baader Bank Aktiengesellschaft - MarketBeat
Veracyte (NASDAQ:VCYT) Rating Lowered to Hold at StockNews.com - MarketBeat
Needham & Company LLC Issues Positive Forecast for Veracyte (NASDAQ:VCYT) Stock Price - MarketBeat
Veracyte Stock Soars to 52-Week High, Reaching $46.12 By Investing.com - Investing.com Australia
Veracyte (NASDAQ:VCYT) Sets New 52-Week High on Analyst Upgrade - Defense World
Veracyte stock price target raised to $51 at Needham - MSN
Veracyte Inc (VCYT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Veracyte Inc 주식 (VCYT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| EPSTEIN ROBERT S | Director |
Jan 06 '25 |
Option Exercise |
8.04 |
20,000 |
160,800 |
64,598 |
| EASTHAM KARIN | Director |
Jan 02 '25 |
Option Exercise |
5.28 |
10,000 |
52,800 |
28,497 |
| EASTHAM KARIN | Director |
Jan 02 '25 |
Sale |
40.30 |
10,000 |
403,006 |
18,497 |
0.06%
3.50%
자본화:
|
볼륨(24시간):